𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma : A prospectively planned combined survival analysis of two multicenter trials

✍ Scribed by Anthony Howell; John Pippen; Richard M. Elledge; Louis Mauriac; Ignace Vergote; Stephen E. Jones; Steven E. Come; C. Kent Osborne; John F.R. Robertson

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
83 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fulvestrant versus anastrozole for the t
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : A prospective combined analysis of two multicenter trials
✍ John F. R. Robertson; C. Kent Osborne; Anthony Howell; Stephen E. Jones; Louis M πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly (_

Anastrozole versus megestrol acetate in
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials
✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace